Cstone cs1003
WebOct 28, 2024 · CS1003 is a humanised recombinant IgG4 monoclonal antibody, currently being evaluated for the treatment of advanced solid tumours, including a global … WebMay 28, 2024 · CStone subsequently formed a strategic collaboration agreement with EQRx, under which EQRx licensed the exclusive rights to two key late-stage immuno-oncology assets, sugemalimab and CS1003 (anti ...
Cstone cs1003
Did you know?
WebOct 27, 2024 · CStone retains rights to CS1003 in Greater China, where it can continue to pursue development as a monotherapy or in combination. Sugemalimab is a PD-L1 antibody that is being developed for high ... WebMay 14, 2024 · Fixed dose at 200mg in combination with CS1002 on a specified dose level. Other Name: anti-PD1. Experimental: CS1003. Participants will receive CS1003 intravenously at fixed dose on specified days. Drug: CS1002. Dose levels will be escalated following a modified 3+3 dose escalation scheme. Other Name: anti-CTLA 4.
WebOct 24, 2024 · Oct 23, 2024, 22:08 ET. SUZHOU, China, Oct. 23, 2024 /PRNewswire/ -- CStone Pharmaceuticals ("CStone") today announced that the United States Food and Drug Administration (FDA) has recently ... WebNov 16, 2024 · CS1003: CStone Pharmaceuticals. CS1003 is a humanized recombinant IgG4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1), which is being developed for immunotherapy of ...
WebApr 28, 2024 · In March 2024, the CS1003-305 study had successfully reached its prespecified enrollment target. About CStone. CStone (HKEX: 2616) is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer … WebJul 12, 2024 · The results of these early experiments have demonstrated that CS1003 has strong potential as a monotherapy and in combination with multiple anticancer agents." About CS1003 and the PD-1/PD-L1 pathway. CS1003 is a humanized anti-PD-1 IgG4 monoclonal antibody developed by CStone using an internationally leading hybridoma …
WebMar 15, 2024 · CStone Pharmaceuticals: ClinicalTrials.gov Identifier: NCT05279300 Other Study ID Numbers: CS5001-101 : First Posted: March 15, 2024 Key Record Dates: Last Update Posted: January 18, 2024 Last Verified: January 2024 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No: Layout table for additional information ...
WebDec 28, 2024 · CS1003 is a humanized IgG4 anti-PD-1 monoclonal antibody developed by CStone's proprietary hybridoma platform and has shown good tolerability and efficacy in in vivo studies. All global rights are ... calstrs employer ratesWebCS1003 is a key pipeline candidate for CStone and is currently progressing smoothly through Phase I trial in Australia. We will continue to push forward CS1003's … calstrs employer contribution rates 2021WebOct 28, 2024 · CStone reaches $1.30bn licensing deal with EQRx. (Credit: bertholdbrodersen from Pixabay.) Chinese pharmaceutical firm CStone has agreed to out-license ex-Greater China rights for two of its late-stage immuno-oncology assets, sugemalimab and CS1003, to US-based biopharmaceutical company EQRx. Under the … calstrs form sb1365aWebNov 23, 2024 · CStone will retain rights to the drug outside of greater China. CS1002, a biosimilar of ipilimumab (Bristol Myers Squibb's Yervoy), is being studied as a treatment for melanoma, hepatocellular carcinoma, and microsatellite instability high or mismatch repair deficient tumors. CStone is also studying it in combination with its anti-PD-1 drug CS1003. calstrs employer contribution rates 2023Web“CS1003 is an anti-PD-1 monoclonal antibody independently developed by CStone. Compared to other anti- PD-1 antibodies that have been launched or are currently under … Currently, CStone has received 10 NDA approvals for its 4 drugs. Among them, … CStone Pharmaceuticals holds 2024 annual general meeting 2024/03/26 - … Address: C1 Building, No. 218, Xinghu Street, Suzhou Industrial Park Zip … Over 20 years of experience in global oncology development and scientific … calstrs employer contribution rates 2019calstrs form 600-hWeb4 beds, 3 baths, 2845 sq. ft. house located at 2403 Stone Castle Cir, College Station, TX 77845. View sales history, tax history, home value estimates, and overhead views. APN … cod ghost extinction